Compare VRCA & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | CLAR |
|---|---|---|
| Founded | 2013 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 104.9M |
| IPO Year | 2018 | 1998 |
| Metric | VRCA | CLAR |
|---|---|---|
| Price | $6.26 | $3.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $4.08 |
| AVG Volume (30 Days) | 38.9K | ★ 432.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | ★ 11.68 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $228,000.00 |
| Revenue This Year | N/A | $5.27 |
| Revenue Next Year | $94.44 | $3.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.72 | $2.53 |
| 52 Week High | $9.82 | $4.03 |
| Indicator | VRCA | CLAR |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 67.03 |
| Support Level | $5.32 | $3.28 |
| Resistance Level | $6.56 | $3.53 |
| Average True Range (ATR) | 0.55 | 0.12 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 59.02 | 96.34 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.